EMA Authorised: Deferasirox Mylan (deferasirox) — Mylan Pharmaceuticals Limited

View source ↗

Summary

The EMA has authorised Deferasirox Mylan for iron overload indications, including beta-thalassemia, with Mylan Pharmaceuticals Limited as the marketing authoris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Iron Overload

Drugs mentioned

• Deferasirox Mylan (deferasirox)

Snippet

Status: Authorised. Therapeutic area: Iron Overload;beta-Thalassemia. MAH: Mylan Pharmaceuticals Limited. Decision date: 08/06/2026